The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
Ghassan K. Abou-Alfa
Research Funding - Chugai Pharma; Roche
Chia-Jui Yen
No relevant relationships to disclose
Jorge A. Carrasquillo
Research Funding - Chugai Pharma
Chih-Hung Hsu
Consultant or Advisory Role - Chugai Pharma; Roche
Research Funding - Chugai Pharma; Roche
Bolorsukh Gansukh
No relevant relationships to disclose
Jennifer Ma
No relevant relationships to disclose
Ellen Hollywood
No relevant relationships to disclose
Peter J Wan
No relevant relationships to disclose
Yu Yun Shao
No relevant relationships to disclose
Zhong-Zhe Lin
No relevant relationships to disclose
Catherine Frenette
Research Funding - Chugai Pharma
Bert H. O'Neil
Research Funding - Chugai Pharma
Lawrence H. Schwartz
Research Funding - Chugai Pharma
Toshihiko Ohtomo
Employment or Leadership Position - Chugai Pharma
Takayoshi Tanaka
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
Ya-Chi Chen
Employment or Leadership Position - Roche
Stock Ownership - Roche
Stacey Ukrainskyj
Employment or Leadership Position - Roche
Stock Ownership - Roche
Leonard Saltz
No relevant relationships to disclose
Reuy-min Lee
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ann-Lii Cheng
Research Funding - Chugai Pharma